[Effectiveness of neoadjuvant chemotherapy for the patients with locally invasive bladder cancer].
OBJECTIVE
To know the survival and prognostic factors of the patients who received radical cystectomy with or without neoadjuvant cisplatin-based chemotherapy.


METHODS
Between 1977 and 2001, 201 patients underwent radical cystectomy at Yokohama City University and Yokosuka Kyosai Hospital whose tumor were clinically diagnosed as locally invasive bladder cancer (T2-4NxM0). Survival rates and 9 prognostic factors (Age, Size, Multiplicity, Type, Grade, p-stage, n,neoadjuvant chemotherapy, adjuvant chemotherapy) were analysed by Kaplan-Meier methods and Cox-proportional hazard model.


RESULTS
The independent prognostic factors of these patients were size, multiplicity, type, grade, p-stage, n, neoadjuvant by univariate analysis. Of these 7 factors, n, neoadjuvant, p-stage and size are significant by multivariate analysis. Survival of the patients who received neoadjuvant cisplatin-based chemotherapy followed cystectomy is better than cystectomy only group by Kaplan-Meier method.


CONCLUSIONS
From these rusults, neoadjuvant cisplatin-based chemotherapy play some role for survival of the patients with invasive bladder cancer.
Noguchi
Sumio
S
Department of Urology, Yokosuka Kyosai Hospital.
Takase
Kazunori
K
Yoshida
Minoru
M
Yumura
Yasushi
Y
Yamashita
Yuzo
Y
Oogo
Yoshiharu
Y
Miyoshi
Yasuhide
Y
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D017024:Chemotherapy, Adjuvant; D002945:Cisplatin / Q000008:administration & dosage; D015653:Cystectomy; D004317:Doxorubicin / Q000008:administration & dosage; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage; D008875:Middle Aged; D015999:Multivariate Analysis; D020360:Neoadjuvant Therapy; D011379:Prognosis; D016016:Proportional Hazards Models; D012189:Retrospective Studies; D015996:Survival Rate; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy* / Q000401:mortality / Q000532:radiotherapy / Q000601:surgery; D014747:Vinblastine / Q000008:administration & dosage
D014747:Vinblastine; D004317:Doxorubicin; D002945:Cisplatin; D008727:Methotrexate